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To compare pharmacokinetic behaviors of nitrendipine submicron emulsion with nitren-
dipine solution following intravenous administration in rats. The plasma concentrations
were analyzed by ultra-performance liquid chromatography coupled with tandem mass
spectrometry detection (UPLCeMS/MS) through a new validated method. The pharmaco-
kinetic parameters of the nitrendipine submicron emulsion and nitrendipine solution were
as follows: AUC0et 900.76 ± 186.59 versus 687.08 ± 66.24 ng h/ml, Cmax 854.54 ± 159.48 versus
610.59 ± 235.99 ng/ml, t1/2 2.37 ± 1.99 versus 2.80 ± 2.69 h. The relative bioavailability of
nitrendipine submicron emulsion to nitrendipine solution was 131.4 ± 11.3%. The devel-
oped methods could meet the requirements of bioanalysis. Compared to the solution in-
jection, intravenous submicron emulsion presents higher systematic exposure which can
help to improve the therapeutic efficacy.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Nitrendipine (NTD) is a widely used calcium channel blocker
belonging to the dihydropyridine class compounds that is
being developed for the treatment of hypertension [1,2]. With
its mild and persistent antihypertensive effect, it was
preferred drug for elderly hypertensive patients. The molec-
ular structure of NTD is showed in Fig. 1.
Due to its low solubility in water (about 2 mg/ml) [3], slow
dissolution rate, and high first-pass effect [4,5], NTD exhibits(T. Zhang).
g Pharmaceutical Univer
University. Production anlow and irregular bioavailability following oral administra-
tion. To improve the solubility, various techniques have been
applied, such as self-microemulsifying drug-delivery system
[6], solid dispersion [7], solid lipid nanoparticles [8,9], nano-
suspensions [10] and inclusion complexation [11]. However,
the commercial dosage forms of NTD are still usual tablets
and capsules only which all display low oral bioavailability.
In recent years, submicron emulsion was applied to
improve the solubility and bioavailability of NTD as a new
drug-delivery system. Composed of well-tolerated excipients,
this drug-delivery system has many advantages including: (1)sity.
d hosting by Elsevier B.V. All rights reserved.
Fig. 1 e The structure of nitrendipine.
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meanwhile avoiding the use of conventional co-solvent sys-
tems; (2) preventing drug hydrolysis and enhancing drug
stability by incorporating it into the interior oil phase; (3)
providing the possibility of sustained-release and targeted
delivery of drugs [12].
The preparation of NTD submicron emulsion has been
described in details by Nana Zhao et al. [13] in her research.
But there is still no study on the intravenous pharmacokinetic
behaviors of nitrendipine submicron emulsion. This paper
established the analysis method of NTD in vitro and got vali-
dations. Then a pharmacokinetic study on rats was preformed
to evaluate whether the bioavailability of NTD was signifi-
cantly improved following intravenous injection of nitrendi-
pine submicron emulsion.2. Materials and methods
2.1. Materials
Nitrendipine was purchased from Shanxi Sciphar Biotech-
nology Co., Ltd. (Shanxi, China). Egg lecithin was purchased
from Shanghai advanced vehicle technology pharmaceutical
Ltd. (Shanghai, China). Soybean oil and medium-chain tri-
glyceride was supplied by Tieling Beiya Pharmaceutical Co.,
Ltd. (Tieling, China). Oleic acid was purchased from Lipoid
GmbH Pharmaceutical Co., Ltd. (Germany). Nimodipine was
purchased from Jinan Dongfeng Pharmaceutical Co., Ltd.
(Jinan, China). Acetonitrile and methanol (HPLC-grade) were
purchased from Fisher Scientific (Pittsburgh, PA, USA). Diethyl
ether was purchased from Tianjin Fuyu Commerce & Trade
Co., Ltd (Tianjin, China), Hexane was purchased from Tianjin
Bodi Commerce & Trade Co., Ltd (Tianjin, China).
2.2. Bioavailability and pharmacokinetic studies of
injection
2.2.1. Drug preparation and administration
The NTD submicron emulsion was prepared using egg leci-
thin, soybean oil, medium-chain triglyceride and oleic acid.
They were mixed evenly and processed by homogenization.
NTD solution: the drug was dissolved by water for injectionwith sodium metabisulfite, niacinamide, propanediol and
ethanol which was mentioned by Nana Zhao et al. [13].
The animal experiments were approved by the Animal
Experiment Ethics Committee of Shenyang Pharmaceutical
University. The in vivo studies were conducted in male Spra-
gueeDawley rats with body weights ranging from 190 g to
210 g which were group-housed (6 animals per cage) with free
access to food and water for at least one week before the
pharmacokinetic study and then the rats were fasted for
approximately 12 h prior to dosing. Each animal was weighed
to ensure that an accurate dose was given. Nitrendipine sub-
micron emulsion injections were used as tests and nitrendi-
pine solution injections as references. According to clinical
dosage of NTD regimen for human, the drug was injected into
the tail vein at a dose of 3.15mg/kgwhichwas translated from
human to rat by the method of BSA. Blood samples (300 ml)
were collected from the orbital plexus and put into heparin-
ized plastic tubes at the following time after dosing: 5, 15, 30,
45min, 1, 2, 4, 6, 8, 12 and 24 h. Then the bloodwas centrifuged
at 3500 rpm for 10 min and stored at 20 C until assay.
2.2.2. UPLCeMS/MS conditions
Liquideliquid extraction technique was used to extract the
drug from plasma samples and nimodipine was used as in-
ternal standard. Generally, 50 ml of the plasma sample was
mixed with 50 ml of internal standard solution (100 ng/ml) and
50 ml of acetonitrileewater (70:30, v/v), then 1 ml of hexane-
diethyl ether was added and vortexed for 3 min followed by
centrifugation at 3500 rpm for 5 min. Then, the upper layer
was collected and dried at 37 C under a stream of nitrogen.
The residue was reconstituted in 100 ml mobile phase by vor-
texmixing (1min) followed by centrifugation at 15,000 rpm for
10 min. Then the upper layer was used for analysis and 5 ml
was injected into UPLCeMS/MS system.
The analyses were performed on a triple-quadrupole mass
spectrometer equipped with an ESI source in positive mode.
The capillary voltage was 3.3 kV, and the cone voltage was
26 V for nitrendipine. The source temperature was 120 C and
the desolvation temperature was 380 C. The cone gas flow
was 50 l/h and the desolvation gas flow was 550 l/h. Quanti-
fication was carried out in the multiple reaction monitoring
mode. The fragmentation transitions werem/z 361/ 315 and
419/ 343 for nitrendipine and nimodipine, respectively. The
separation was performed on an ACQUITY UPLC™ BEH C18
column (50 mm  2.1 mm, 1.7 mm, Milford, MA, USA) with
acetonitrileewater (70:30, v/v) as the mobile phase at a flow
rate of 0.2 ml/min. The column temperature was set at 40 C.
All data were acquired and processed using MassLynx 4.1
software with the QuanLynx program (Waters Corp., Milford,
MA, USA).
2.2.3. Method validation
Validation of UPLCeMS/MS method was evaluated by limit of
quantification, linearity, precision, accuracy and stability. The
limit of quantification (LLOQ) was defined as the concentra-
tion with a peak to peak signal-to-noise ratio of 10. A 1/x2-
weighted least-squares linear regression was applied to the
calibration standards using the peak area ratio of analyst to
internal standard. Intra- and inter-day precision and accuracy
were evaluated as the relative standard deviation (RSD) by
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consecutive d. The absolute recovery was determined by
comparing the mean peak areas of six extracted samples at
low, medium, and high QC concentrations with the mean
peak areas of the corresponding standard samples. The post-
preparative stability of extracted samples in the autosampler
rack at room-temperature for 12 h, the room-temperature
stability (22 C for 4 h) and freeze-thaw stability
(20 Ce22 C) were evaluated by analyzing low, medium and
high QC samples (n ¼ 3).
2.2.4. Pharmacokinetic and statistical analysis
The pharmacokinetic parameters were analyzed by using a
pharmacokinetic program DAS 2.0. The mean peak concen-
tration (Cmax) and peak time (Tmax) were obtained directly
from the concentration-time curve. The elimination rate
constant (ke) was obtained from the linear fitted log-linear of
the plasma concentration-time profile. The elimination half
life (t1/2) was calculated as 0.693/ke. The area under the
concentration-time curve to the last time point (AUC0-t) was
estimated according to the linear trapezoidal rule.
The statistical analysis was performed using analysis of
variance (ANOVA) at a significance level of P < 0.05.Fig. 2 eMassspectrumofnitrendipine (A)andnimodipine (B).3. Results and discussion
3.1. Mass spectrometry
The ion scan spectra of nitrendipine are shown in Fig. 2. The
main mass spectrometry parameters, such as the source
temperature, the capillary voltage, cone voltage and collision
energy were optimized to get the sensitive response.
3.2. Extraction solvent
In order to choose a suitable solvent to extract the drug from
plasma, several solvents were investigated by comparing the
extraction recoveries. These solvents included diethyl ether,
ethyl acetate, cyclohexane and isopropyl alcohol which were
employed in other earlier methods [14e17]. But these solvents
showed a low extraction recovery (about 20%e60%). By using a
binary solvent of hexane-diethyl ether (1:1), a high extraction
recovery (above 84%) was obtained. So hexane-diethyl ether
(1:1) was chosen to extract the drug from plasma.
3.3. Method validation
Fig. 3 shows the typical chromatograms of blank plasma,
plasma spiked with analyte and IS and a plasma sample from
a rat after injection. It shows that no significant interferences
from the endogenous plasma components were observed at
the retention times of the analyst and the IS.
The calibration curve of nitrendipine shows a good line-
arity over the concentration range of 5e1250 ng/ml
(r ¼ 0.9975). The typical equations of the calibration curves
using linear regression analysis were as follows:
y ¼ 4.3x þ 29.19, where y is the peak area ratio of nitrendipine
to the IS and x is the concentration of nitrendipine added to
the plasma. The lowest limit of quantitation (LLOQ) was 5 ng/ml. The precision at the corresponding LLOQ level was less
than 15% and the accuracy was in the range of 80%e120%.
The recoveries of nitrendipine in three QC concentration
levels (10, 250 and 1000 ng/ml) were shown in Table 1. The
mean recoveries were 84.1 ± 8.18%, 97.1 ± 3.07% and
97.4 ± 2.96%, respectively. The mean absolute recovery of the
internal standard was 97.6 ± 2.79%. All recoveries had a RSD
less than 9.73% at three different concentrations, showing
good assay consistency, precision and reproduction.
The intra- and inter-day precision and accuracy were
within the acceptable range of ±15% and these results indi-
cated that themethod is accurate and precise. Stability results
showed good stability of nitrendipine in rat plasma under the
indicated conditions.
When this method is used, the analysis time for a single
injection is just 4 min, therefore, the current UPLCeMS/MS
method was considered as an appropriate method for the
simple, sensitive and rapid determination of nitrendipine in
plasma.3.4. Pharmacokinetics
The mean plasma concentration-time curves and the key
pharmacokinetic parameters are shown in Fig. 4 and Table 2,
Fig. 3 e (A) A blank rat plasma; (B) a blank rat plasma spiked with nitrendipine at 500 ng/ml and internal standard
(nimodipine, 100 ng/ml); (C) rat plasma obtained from a rat 15 min after administration of nitrendipine. Peak Ⅰ, nimodipine;
Peak Ⅱ, nitrendipine.
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Table 1 e The recovery data of nitrendipine from rat
plasma (n ¼ 6).
C (ng/ml) Nitrendipine Nimodipine
10 250 1000 100
Mean ± SD
(%)
84.1 ± 8.18 97.1 ± 3.07 97.4 ± 2.96 97.6 ± 2.79
RSD (%) 9.73 3.16 3.03 2.86
Fig. 4 e Mean concentration-time curves after
administrating the test and reference formulations.
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the submicron emulsionwere significantly increased (P < 0.05)
compared with that of usual solution. The Cmax was about
854.54 and 610.59 ng/ml for nitrendipine submicron emulsion
and nitrendipine solution, respectively. This similar finding as
Kun Gao et al. [18] suggested that incorporation of durg into
lipid emulsion may increase its effective plasma concentra-
tion. The AUC0-t for nitrendipine submicron emulsion was
900.76 ng h/ml, about 1.3-fold higher than that of nitrendipine
solution. In summary, the submicron emulsion showed a
faster and better pharmacokinetic profile than the solution.
The plasma concentration-time curves revealed that the
submicron emulsion shows a significantly higher plasma
concentration after 45 min of injection than solution formu-
lation. This phenomenon can be explained by the state of
nitrendipine in the two formulations. In the solution, nitren-
dipine existing as the molecule state can be eliminated fromTable 2 e Pharmacokinetic parameters of nitrendipine
after i.v. administration (data were expressed as







Cmax (ng/ml) 854.54 ± 159.48
* 610.59 ± 235.99
t1/2 (h) 2.37 ± 1.99 2.80 ± 2.69
AUC0et (ng$h/ml) 900.76 ± 186.59* 687.08 ± 66.24
F (%) 131.4 ± 11.3 100
*P < 0.05 versus nitrendipine solution injections as controls.plasma rapidly. But in the submicron emulsion, nitrendipine
was entrapped into the interior oil phase, so it was slowly for
the drug to release from the carrier. This result attributed to
the effect of sustained-release, which was in agreement with
the report [19,20]. And it did not have dose dumping phe-
nomenon in vivo. This result meant that the NTD submicron
emulsion also had good stability in vivo compare with the
results of stability studies in vitro from Nana Zhao et al. [13].4. Conclusion
This paper established a rapid, sensitive and accurate
UPLCeMS/MS method to study the pharmacokinetics of
netrendipine submicron emulsion in rats. The submicron
emulsion showed a better absorption than the solution. The
results suggest that it is a promising way to improve the
bioavailability of poorly soluble drugs by the application of
submicron emulsion.r e f e r e n c e s
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